JANXNasdaqPharmaceutical PreparationsFiscal year ends December 31

Janux Therapeutics, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026

$16.74+0.23 (+1.39%)

Close on Oct 19, 2026

Market cap: $1.05B
P/E (TTM): –
Dividend yield: –

Janux Therapeutics, Inc. balance sheet

Annual Quarterly

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31
Cash & Equivalents	52	431	19	51	36	7.81	–
Short-Term Investments	914	595	325	276	339	0	–
Cash & Short-Term Investments	967	1,025	344	327	375	7.81	–
Receivables	0	–	0	0	0	8.00	–
Prepaid Expenses & Other	9.32	8.49	5.21	5.42	2.05	0.25	–
Total Current Assets	976	1,034	349	332	377	16	–
Property, Plant & Equipment	3.85	4.86	7.00	7.09	1.41	0.16	–
Gross Property, Plant & Equipment	11	9.82	9.92	8.06	1.54	0.18	–
Accumulated Depreciation	-6.97	-4.95	-2.91	-0.97	-0.13	-0.02	–
Operating Lease Right-of-Use Assets	18	19	21	22	0.19	0	–
Other Long-Term Assets	2.61	2.88	2.51	1.39	0.39	0	–
Total Assets	1,002	1,062	380	364	380	16	–
Accounts Payable	4.97	4.03	2.42	2.16	2.46	0.43	–
Accrued Expenses	18	12	7.39	8.18	3.78	0.75	–
Current Portion of Leases	2.39	1.75	1.52	0.76	0.19	0	–
Deferred Revenue (Current)	0	0	1.71	5.41	5.16	1.95	–
Total Current Liabilities	25	17	13	17	13	3.18	–
Long-Term Leases	20	21	23	25	0	0	–
Operating Lease Liabilities	22	23	25	25	0.19	0	–
Total Liabilities	45	39	36	43	13	9.23	–
Preferred Stock	0	–	–	–	–	–	–
Common Stock	0.06	0.06	0.05	0.04	0.04	0.00	–
Additional Paid-In Capital	1,304	1,258	512	433	414	0.10	–
Retained Earnings	-351	-238	-169	-110	-47	-15	–
Comprehensive Income & Other	4.32	2.16	0.67	-1.54	-0.27	0	–
Shareholders' Equity	957	1,023	344	321	366	-15	-7.94
Total Equity	957	1,023	344	321	366	-15	-7.94
Total Liabilities & Equity	1,002	1,062	380	364	380	16	–
Shares Outstanding(shares)	60	59	46	42	41	1.05	–
Allowance for Credit Losses	0	0	0	–	–	–	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: –
Operating margin: -598.1%
Net margin: -427.5%
Return on equity, FY2025: -11.5%

Financial strength

Current ratio: 16.35
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 46.2%

Valuation

P/E ratio: –
Price to sales: 43.90
Price to book: 1.14
Dividend yield: –